

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
Phillip Mark Hogarth		08/28/2007
Bruce David Wines		08/28/2007
RECEIVING PARTY DATA		
Name:	Trillium Therapeutices, Inc.	
Street Address:	96 Skyway Avenue	
City:	Toronto	
State/Country:	CANADA	
Postal Code:	M9W 4Y9	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	11762664	
CORRESPONDENCE DATA		
Fax Number:	(303)863-0223	
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Email:	DYoerg@sheridanross.com	
Correspondent Name:	Sheridan Ross P.C.	
Address Line 1:	1560 Broadway Street	
Address Line 2:	Suite 1200	
Address Line 4:	Denver, COLORADO 80202	
ATTORNEY DOCKET NUMBER:	5644TT-2	
NAME OF SUBMITTER:	Darla G. Yoerg	
Total Attachments: 1 source=Assignment#page1.tif		

CH \$40.00 11762664

500355427

PATENT
REEL: 019833 FRAME: 0708

ASSIGNMENT

WHEREAS, we, Phillip Mark Hogarth of 6 Robertson Street, Williamstown, Victoria AUSTRALIA 3016, and Bruce David Wines of 48 Anderson Street, Heidelberg, Victoria AUSTRALIA 3084, have invented a certain new and useful invention entitled Multimeric Fc Receptor Polypeptides, for which an application for Letters Patent of the United States has been prepared and filed on June 13, 2007, receiving Serial No. 11/762,664, and further identified as Attorney File No. 5644TT-2;

NOW THEREFORE, be it known that we, the said inventors, for and in consideration of certain good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, at the request of the assignee do sell, assign and transfer unto said assignee, Trillium Therapeutics, Inc., Canada corporation having a place of business at 96 Skyway Avenue, Toronto, Ontario CANADA M9W 4Y9, its successors, legal representatives and assigns, the aforesaid application for the territory of the United States of America and all continuation, divisional, continuation-in-part and reissue applications, all patent applications in foreign countries, all applications pursuant to the Patent Cooperation Treaty, and all applications for extension filed or to be filed for the invention, and all Letters Patent, Invention Registrations, Utility Models, Extensions or Reissues and other patent rights, obtained for the invention in the United States or any other country; we also assign any right, title or interest in and to the invention which has not already been transferred to the assignee; we warrant that we have made no assignment of the invention, application or patent therefor to a party other than Trillium Therapeutics, Inc. and we are under no obligation to make any assignment of the invention, application, or patent therefor to any other party; and we further agree to cooperate with the assignee hereunder in the obtaining and sustaining of any and all such Letters Patent and in confirming assignee's exclusive ownership of the invention, but at the expense of said assignee.

The Commissioner of Patents is hereby authorized and requested to issue the Letters Patent solely in accordance with the terms of this Assignment, to Trillium Therapeutics, Inc., its successors, legal representatives and assigns, as the assignee of the entire right, title and interest therein.

IN WITNESS WHEREOF, the parties hereto have executed this Assignment as of the date indicated hereunder.

Date: 28-08-07

By: 
Phillip Mark Hogarth

Date: 28/8/07

By: Bruce D. Wines
Bruce David Wines